BioCryst Pharmaceuticals, Inc. Stock Incentive Plan Amendment

BioCryst Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders on June 11, 2026. At this meeting, stockholders approved an amendment and restatement of the Company's Stock Incentive Plan. This amendment increases the number of shares available for issuance under the plan by 7,000,000. The updated plan, effective April 20, 2026, aims to incentivize employees, non-employee directors, and consultants by allowing them to acquire proprietary interests in the Company. The plan is structured into three programs: Discretionary Option Grants, Stock Issuance, and Director Grants. Key provisions include a minimum vesting period of 12 months (with exceptions for death, disability, or change in control), limitations on the number of shares an individual can receive annually, and adjustments for corporate events like stock splits or dividends. The total number of shares available under the amended plan is now 88,090,000. The company also reported the election of directors, ratification of auditors, and advisory vote on executive compensation.